Stock VAXX VAXXINITY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vaxxinity, Inc.

Equities

VAXX

US92244V1044

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		After market 22:15:03
0.1411 USD +35.41% Intraday chart for Vaxxinity, Inc. 0.137 -2.91%
04-22 Sector Update: Health Care Stocks Advance Premarket Monday MT
04-22 Sector Update: Health Care MT

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 703.5 176.5 107.7
Enterprise Value (EV) 1 564.9 104 92.27
P/E ratio -3.13 x -2.34 x -1.89 x
Yield - - -
Capitalization / Revenue 10,658,499,773 x - -
EV / Revenue 8,559,030,076 x - -
EV / EBITDA -4.56 x -1.4 x -1.65 x
EV / FCF -16,999,131 x -2,954,896 x -2,468,516 x
FCF Yield -0% -0% -0%
Price to Book 5.47 x 2.84 x 8.03 x
Nbr of stocks (in thousands) 125,394 126,056 126,746
Reference price 2 5.610 1.400 0.8500
Announcement Date 24/03/22 27/03/23 27/03/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales - 0.557 0.066 - -
EBITDA 1 -13.55 -31.56 -124 -74.3 -56.05
EBIT 1 -13.66 -32.28 -125.1 -75.98 -58.28
Operating Margin - -5,795.69% -189,507.58% - -
Earnings before Tax (EBT) 1 -14.16 -39.96 -137.2 -75.22 -56.93
Net income 1 -14.22 -39.96 -137.2 -75.22 -56.93
Net margin - -7,173.61% -207,840.91% - -
EPS 2 -0.4156 -0.6087 -1.791 -0.5973 -0.4500
Free Cash Flow - -21.17 -33.23 -35.19 -37.38
FCF margin - -3,801.32% -50,349.81% - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 06/08/21 06/08/21 24/03/22 27/03/23 27/03/24
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3
Net sales 1 -0.001 - - - - - - -
EBITDA -47.42 - - - - - -13.89 -
EBIT 1 -47.85 -18.16 -17.22 -19.77 -20.82 -18.81 -14.43 -13.44
Operating Margin 4,785,400% - - - - - - -
Earnings before Tax (EBT) 1 -48.19 -18.26 -17.25 -19.25 -20.46 -18.42 -13.98 -13.14
Net income 1 -48.19 -18.26 -17.25 -19.25 -20.46 -18.42 -13.98 -13.14
Net margin 4,819,100% - - - - - - -
EPS 2 -0.4900 -0.1500 -0.1400 -0.1500 -0.1700 -0.1500 -0.1100 -0.1000
Dividend per Share - - - - - - - -
Announcement Date 24/03/22 09/05/22 11/08/22 10/11/22 27/03/23 09/05/23 09/08/23 08/11/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 13.9 7.15 - - -
Net Cash position 1 - - 139 72.5 15.5
Leverage (Debt/EBITDA) -1.022 x -0.2266 x - - -
Free Cash Flow - -21.2 -33.2 -35.2 -37.4
ROE (net income / shareholders' equity) - 172% -265% -78.9% -151%
ROA (Net income/ Total Assets) - -78% -72.1% -34.8% -48.3%
Assets 1 - 51.23 190.2 216.3 117.8
Book Value Per Share 2 -1.420 -1.280 1.030 0.4900 0.1100
Cash Flow per Share 2 0.0100 0.4600 1.160 0.2700 0.0400
Capex - 1.48 1.32 1.87 0.8
Capex / Sales - 265.17% 1,996.97% - -
Announcement Date 06/08/21 06/08/21 24/03/22 27/03/23 27/03/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VAXXINITY, INC. Stock Vaxxinity, Inc.
-83.40% 13.21M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 48.09B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.43B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.36B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 24.89B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.01B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 11.88B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.8B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VAXX Stock
  4. Financials Vaxxinity, Inc.